Research Centre of the Portuguese Oncology Institute of Lisbon Francisco Gentil

The Research Centre of the Portuguese Oncology Institute of Lisbon Francisco Gentil (CI-IPO Lisboa) is a national and European reference in integrated cancer research, operating at the interface of scientific excellence and patient-centred clinical practice. Embedded within a leading clinical cancer centre accredited by the Organisation of European Cancer Institutes (OECI), CI-IPO Lisboa is committed to advancing basic, translational, clinical, epidemiological, and nursing research that directly improves cancer care, fosters innovation, and supports health policy refinement.

CI-IPO Lisboa comprises four dedicated research units namely, the Molecular Pathobiology Research Unit, Clinical Research Unit, Nursing Research Unit, and Epidemiology Research Unit, and a certified national Tumour Biobank, a founding member of Biobank.pt.

With over 300 members involved in research activities, including nearly 200 healthcare professionals and 50 full-time researchers, it currently supports 62 active clinical trials (phases II-IV) and 204 observational studies.

Its scientific outputs include an average of 217 scientific publications per year, with a growing number in high-impact journals (19 publications with IF >10 in 2024). Notable Publications: PMID 38705160, 38906616, 38421814, 38437507, 38754055.

CI-IPO Lisboa is actively engaged in major international consortia and networks, including EORTC, EURACAN, PAEDCAN, GENTURIS, ESLHO, and SIOP Europe, fostering collaborative oncology research at European scale.

Currently, CI-IPO Lisboa is involved in 7 EU-funded projects, including 2 under the EU Cancer Mission, reinforcing its strategic role in translational oncology research and the clinical advancement of innovative solutions.

Driven by a mission to strengthen international visibility, CI-IPO Lisboa is seeking to expand its role in shaping future cancer research and clinical innovation. With strong clinical-research integration across services like haematology, paediatrics, pathology, and nursing, CI-IPO Lisboa seeks to co-develop proposals under EU Cancer Mission, particularly those related to paediatric oncology, innovative surgical approaches and quality-of-life interventions in older cancer patients.

CI-IPO Lisboa offers a dynamic and clinically embedded research platform with a proven track record in European R&I. For collaboration opportunities, please contact the profile of Tânia Cruz through the platform or follow-up by e-mail ipol.centroinvestigacao@ipolisboa.min-saude.pt.